Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Gregory A Reichard"'
Autor:
William F. McCarthy, Donna Tosh, Kristopher M Paolino, Meshell N Morrison, James E Moon, Sean R Marcsisin, Jason W. Bennett, Christian A Darko, Qigui Li, Patrick Twomey, Philip L Smith, Brittney M Potter, Gregory A Reichard, Susan B Cicatelli, Brandon S Pybus, Kristin T Mills, Jeffrey W Froude, Thomas G Oliver, Michele D. Spring, Norman C. Waters, Jason C Sousa
Publikováno v:
The Journal of Infectious Diseases
BackgroundPlasmodium vivax malaria requires a 2-week course of primaquine (PQ) for radical cure. Evidence suggests that the hepatic isoenzyme cytochrome P450 2D6 (CYP2D6) is the key enzyme required to convert PQ into its active metabolite.MethodsCYP2
Autor:
Anchalee Tungtaeng, John H. Adams, Christina K. Nolan, Pattaraporn Vanachayangkul, Piyaporn Saingam, Philip L. Smith, Matthew D Wegner, Gregory A. Reichard, Richard J. Sciotti, Brian Vesely, Rawiwan Imerbsin, Kevin C. Kobylinski, Chanikarn Kodchakorn, Chad C. Black, Alison Roth, Chaiyaporn Chaisatit, Luis A Lugo, Brandon S. Pybus, Mariusz Wojnarski
Previously, ivermectin (1–10 mg/kg) was shown to inhibit liver-stage development of Plasmodium berghei in orally dosed mice. Here, ivermectin showed inhibition of the in vitro development of Plasmodium cynomolgi schizonts (IC50 = 10.42 μM) and hyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8682b0a3b1f0cf282ebc46b6c374733c
https://doi.org/10.1101/2020.04.27.065409
https://doi.org/10.1101/2020.04.27.065409
Autor:
Mariusz Wojnarski, Chanikarn Kodchakorn, Alison Roth, Luis A Lugo-Roman, Chaiyaporn Chaisatit, Pattaraporn Vanachayangkul, Philip L. Smith, Christina K. Nolan, John H. Adams, Chad C. Black, Kevin C. Kobylinski, Anchalee Tungtaeng, Rawiwan Imerbsin, Richard J. Sciotti, Brian Vesely, Piyaporn Saingam, Gregory A. Reichard, Brandon S. Pybus, Matthew D Wegner
Publikováno v:
Antimicrobial Agents and Chemotherapy
Previously, ivermectin (1 to 10 mg/kg of body weight) was shown to inhibit the liver-stage development of Plasmodium berghei in orally dosed mice. Here, ivermectin showed inhibition of the in vitro development of Plasmodium cynomolgi schizonts (50% i
Autor:
Diana Caridha, Qigui Li, Jangwoo Lee, Dylan Nugent, Susan E. Leed, Kirk Butler, Erin Milner, Eve Hosford, Amanda Schenk, Franklyn Ngundam, Richard J. Sciotti, Brian Vesely, Norma Roncal, Mara Kreishman-Deitrick, Chad C. Black, Patricia J. Lee, Mark Hickman, Lisa Xie, Gregory A. Reichard
Publikováno v:
Malaria Journal
Malaria Journal, Vol 18, Iss 1, Pp 1-15 (2019)
Malaria Journal, Vol 18, Iss 1, Pp 1-15 (2019)
Background Rodent malaria models are extensively used to predict treatment outcomes in human infections. There is a constant need to improve and refine these models by innovating ways to apply new scientific findings and cutting edge technologies. In
Autor:
Gregory A. Reichard, Sean R. Marcsisin, Rosemary Rochford, Paul C. Baresel, Jason C. Sousa, Larry A. Walker, Chau T. Vuong, Kristina S. Wickham, Brice Campo, Babu L. Tekwani
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:5906-5913
Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) are at risk for developing hemolytic anemia when given the antimalarial drug primaquine (PQ). The WHO Evidence Review Group released a report suggesting that mass administra
Autor:
Jason W Bennett, Gregory A Reichard, Philip L Smith, Norman C Waters, William F Mccarthy, Thomas G Oliver, Brandon S Pybus, Jeffrey W Froude, Susan B Cicatelli, Donna M Tosh, James E Moon, Patrick S Twomey, Kristopher M Paolino, Brittney M Potter, Kristin T Mills, Sean R Marcsisin, Meshell N Morrison, Christian A Darko, Qigui Li, Jason C Sousa, Michele D Spring
Publikováno v:
The Journal of Infectious Diseases
Plasmodium vivax malaria requires a 2-week course of primaquine (PQ) for radical cure. Evidence suggests that the hepatic isoenzyme cytochrome P450 2D6 (CYP2D6) is the key enzyme required to convert PQ into its active metabolite.CYP2D6 genotypes and
Autor:
Larry A. Walker, Rajnish Sahu, Gregory A. Reichard, H. M. T. Bandara Herath, N. P. Dhammika Nanayakkara, Babu L. Tekwani, Frank R. Fronczek, Anchalee Tungtaeng, James D. McChesney, Paul C. Baresel, Kristina S. Wickham, Yvonne Van Gessel, Victor Melendez, Rosemary Rochford, Marilyn S. Bartlett, Colin Ohrt, Montip Gettayacamin
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:4737-4744
Hematotoxicity in individuals genetically deficient in glucose-6-phosphate dehydrogenase (G6PD) activity is the major limitation of primaquine (PQ), the only antimalarial drug in clinical use for treatment of relapsing Plasmodium vivax malaria. PQ is
Autor:
Jason C. Sousa, Corttney Potter, Qigui Li, Mark Hickman, Brandon S. Pybus, Jing Zhang, Mara Kreishman-Deitrick, ThuLan Luong, Lisa Xie, Chau Vuong, Philip L. Smith, Jennifer Nelson, Sean R. Marcsisin, Gregory A. Reichard, Xiannu Jin, Brittney Potter, Ping Zhang, Robert Paris
Publikováno v:
Malaria Journal
Background The liver-stage anti-malarial activity of primaquine and other 8-aminoquinoline molecules has been linked to bio-activation through CYP 2D6 metabolism. Factors such as CYP 2D6 poor metabolizer status and/or co-administration of drugs that
Autor:
James D. McChesney, Pius S. Fasinu, Babu L. Tekwani, N. P. Dhammika Nanayakkara, Mahmoud A. ElSohly, Gregory A. Reichard, Yan-Hong Wang, Ikhlas A. Khan, Bharathi Avula, H. M. T. Bandara Herath, Sean R. Marcsisin, Larry A. Walker, Shabana I. Khan
Publikováno v:
Malaria Journal
Background The clinical utility of primaquine (PQ), used as a racemic mixture of two enantiomers, is limited due to metabolism-linked hemolytic toxicity in individuals with genetic deficiency in glucose-6-phosphate dehydrogenase. The current study in
Autor:
Gregory A. Reichard, Sean R. Marcsisin, Lisa H. Xie, Brittney Potter, Qigui Li, N. P. Dhammika Nanayakkara, Jason C. Sousa, Victor E. Zottig, Chau Vuong, Bryan Smith, Richard J. Sciotti, Brandon S. Pybus, Robert Paris, Philip L. Smith, Babu L. Tekwani, Larry A. Walker, Jing Zhang, Ping Zhang, Christina K. Nolan, Dehui Duan, Lisa Read
Cytochrome P450 (CYP) 2D metabolism is required for the liver-stage antimalarial efficacy of the 8-aminoquinoline molecule tafenoquine in mice. This could be problematic for Plasmodium vivax radical cure, as the human CYP 2D ortholog (2D6) is highly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6de54b8563e8e72b7ebcb6e6ef14602b
https://europepmc.org/articles/PMC4468667/
https://europepmc.org/articles/PMC4468667/